2026-03-22 12:45:00 | Research This article summarizes published peptide research. All content is presented for research reference only and is not intended as medical advice or guidance for personal peptide use. Products referenced are research compounds — not for human consumption, diagnostic or therapeutic application. Inflammation is an ancient defence mechanism: an acute response to infection or injury that mobilises immunity and triggers tissue repair.

The problem starts when the inflammatory signal fails to shut down. Low-grade smouldering inflammation (silent inflammation, inflammaging) underlies atherosclerosis, type 2 diabetes, neurodegeneration, and autoimmune disease. This is where peptides shine: they don't blanket-suppress the defence like NSAIDs, but steer signalling cascades back toward physiological balance. Chronic inflammation — the silent enemy Acute inflammation lasts hours to days and ends with resolution — an active process involving pro-resolving mediators.

Chronic inflammation is a resolution failure: macrophages don't switch from M1 to M2, neutrophils keep releasing ROS, and lymphocytes secrete pro-inflammatory cytokines for months. The link with cardiovascular disease is in PubMed 11160116 . The same mechanisms drive insulin resistance, depression, and neurological disorders. NSAIDs are effective for acute pain but cause gastropathy and renal dysfunction with prolonged use.

Peptides modulate inflammation through specific nodes, preserving the body's ability to respond to real threats. Broader review — healing peptides guide . Signs of chronic inflammation Persistently elevated hs-CRP (>1 mg/L) Morning joint stiffness >30 minutes Ongoing fatigue despite adequate sleep Elevated NLR (neutrophil/lymphocyte >2.5) New food intolerances that weren't there before Biochemical targets of peptides To understand why some peptides work for gut inflammation while others hit arthritis, look at four key molecular nodes. NF-κB — master inflammation TF, bound to IκB in the cytoplasm.

Pro-inflammatory stimuli (LPS, TNF-α, oxidative stress) degrade IκB and let NF-κB reach the nucleus to drive cytokine genes. TB-500 and partially BPC-157 block this step; see PubMed 28011556 . MC1R — G-protein-coupled receptor on macrophages and enterocytes. Its natural ligand α-MSH has anti-inflammatory activity.

KPV is the C-terminal tripeptide that preserves the anti-inflammatory effect without melanocortin side effects — PubMed 20145187 . IL-6, TNF-α, IL-1β — marker cytokine trio. IL-6 drives hepatic CRP, TNF-α activates NF-κB, IL-1β is processed by NLRP3. A 6–8 week protocol lowers these 1.5–2× in research models.

NLRP3 inflammasome — multiprotein complex activating caspase-1 to produce IL-1β. Involved in gout, diabetes, atherosclerosis, Alzheimer's. KPV partially inhibits NLRP3 through MC1R. Target Role in inflammation Modulating peptides Clinical relevance NF-κB Master inflammation TF TB-500, BPC-157, Tα1 Systemic, autoimmune MC1R Receptor for anti-inflammatory α-MSH KPV, α-MSH analogs Skin, gut, autoimmune IL-6/JAK/STAT Main driver of chronic CRP TB-500, KPV, BPC-157 Cardiometabolic TNF-α Triggers and amplifies NF-κB TB-500, Tα1 RA, Crohn's NLRP3 inflammasome IL-1β processing KPV, BPC-157 Gout, diabetes, AD Tight junctions Gut barrier function BPC-157, KPV Leaky gut, IBS, systemic TB-500 — systemic anti-inflammatory TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4).

Best known for recovery, but anti-inflammatory action is equally important. In myocardial injury, Tβ4 cut IL-6 35–45% and TNF-α 25–40% over 4 weeks ( PubMed 17981560 ). In wounds, Tβ4 accelerated keratinocyte migration while reducing neutrophil infiltration ( PubMed 16036211 ). Mechanism is dual: TB-500 binds G-actin and regulates progenitor migration ( PubMed 20237584 ), and blocks NF-κB nuclear translocation.

In tendinitis, TB-500 accelerated recovery and cut infiltrate ( PubMed 27383837 ). See TB-500 vs TB-4 , TB-500 for inflammation , and TB-500 heart repair . Anti-inflammatory TB-500 protocol Loading phase: 2 mg SC twice weekly for 4 weeks Maintenance: 2 mg weekly for 4–8 weeks Half-life ~48 h; injections can be close to the affected area Reconstitution: see the bacteriostatic water guide Parameter Loading Maintenance Minimum course Dose 2 mg × 2/wk 2 mg × 1/wk 6 weeks Route SC SC SC or local Expected IL-6 drop ~25% by week 2 up to 40% by week 6 depends on baseline Expected TNF-α drop ~20% up to 35% ELISA KPV — the mini α-MSH KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. Despite its size, KPV retains full anti-inflammatory activity by binding MC1R on macrophages and enterocytes, minus melanocortin side effects.

In colitis models KPV reduced myeloperoxidase 40–55% and cut mucosal lesion area in half ( PubMed 23106543 ). KPV is active via SC, oral (resistant to gut peptidases), and topical routes — particularly versatile in skin and gut research. See KPV in KLOW . It is also part of the KLOW stack, available as a injection pen .

Area studied Route Typical dose Duration UC, Crohn's Oral 500 mcg 2×/day 6–8 weeks Atopic dermatitis Topical cream 0.1% 2×/day on lesions 4 weeks Psoriasis SC + topical 200 mcg SC + cream 6 weeks Systemic inflammation SC 200–500 mcg/day 6 weeks Post-COVID syndrome SC or oral 500 mcg/day 4–6 weeks BPC-157 and the gut-immune axis BPC-157 is a pentadecapeptide from gastric juice. Not a classical anti-inflammatory, but it indirectly lowers systemic inflammation by restoring gut barrier function. Leaky gut lets LPS and food antigens enter circulation and sustain smouldering inflammation. Oral BPC-157 (250 mcg 2×/day) restores ZO-1/occludin and cuts zonulin 60% over 6 weeks.

Angiogenic effects — PubMed 22087775 , tendon protection — PubMed 20331389 , GI motility — PubMed 28928275 . See BPC-157 dosing , gut-immune axis , IBS , and BPC-157 vs GHK-Cu . Less known anti-inflammatory peptides Thymosin α-1 (Tα1) is a 28-aa thymic peptide. Its main action is immunomodulation: activation of regulatory T cells (Tregs), Th1/Th2 balance, restoration of NK-cell function.

Tα1 is approved in several countries for chronic viral infections (HBV, HCV) and studied in sepsis and oncology — review in PubMed 22238415 . LL-37 (cathelicidin) is a 37-aa cationic peptide produced by neutrophils and epithelial cells. It has antimicrobial activity against bacteria, viruses, and fungi, plus immunoregulatory properties: cytokine modulation and a role in resolution. Detailed review in PubMed 23637782 .

Use is limited to chronic bacterial infections in research protocols. PT-141 (Bremelanotide) is a melanocortin analog developed as an MC3R/MC4R agonist for sexual dysfunction with anti-inflammatory activity via melanocortin system activation. Main use is not anti-inflammatory, but it's worth noting as a member of the α-MSH analog family. Related contexts — livre en France, Belgique, Suisse et Luxembourg — expédition rapide, qualité certifiée, livraison gratuite dès 150 €.

Lire la suite : Guide de recherche sur les peptides anti-inflammatoires — Research